JP2022545181A5 - - Google Patents

Info

Publication number
JP2022545181A5
JP2022545181A5 JP2022507705A JP2022507705A JP2022545181A5 JP 2022545181 A5 JP2022545181 A5 JP 2022545181A5 JP 2022507705 A JP2022507705 A JP 2022507705A JP 2022507705 A JP2022507705 A JP 2022507705A JP 2022545181 A5 JP2022545181 A5 JP 2022545181A5
Authority
JP
Japan
Prior art keywords
cancer
alkyl
compound according
aryl
membered heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022507705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545181A (ja
JP7698317B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048712 external-priority patent/WO2021042022A1/en
Publication of JP2022545181A publication Critical patent/JP2022545181A/ja
Publication of JP2022545181A5 publication Critical patent/JP2022545181A5/ja
Application granted granted Critical
Publication of JP7698317B2 publication Critical patent/JP7698317B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022507705A 2019-08-30 2020-08-31 がん治療のためのセプチン阻害剤 Active JP7698317B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962894424P 2019-08-30 2019-08-30
US62/894,424 2019-08-30
PCT/US2020/048712 WO2021042022A1 (en) 2019-08-30 2020-08-31 Septin inhibitors for treatment of cancers

Publications (3)

Publication Number Publication Date
JP2022545181A JP2022545181A (ja) 2022-10-26
JP2022545181A5 true JP2022545181A5 (enExample) 2023-08-21
JP7698317B2 JP7698317B2 (ja) 2025-06-25

Family

ID=72517327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022507705A Active JP7698317B2 (ja) 2019-08-30 2020-08-31 がん治療のためのセプチン阻害剤

Country Status (4)

Country Link
US (1) US12433876B2 (enExample)
EP (1) EP4021894A1 (enExample)
JP (1) JP7698317B2 (enExample)
WO (1) WO2021042022A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205785A2 (en) * 2022-04-22 2023-10-26 The Board Of Regents Of The University Of Texas System An anticancer therapy targeting ras and other oncogenic signals by inhibition of dynamic blebbing and/or septins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426031A (en) 1967-01-19 1969-02-04 Dow Chemical Co 3,5,6 - trichloro - 4 - (3 - (alpha,alpha,alpha,alpha',alpha',alpha'-hexafluoro - 3,5 - xylyl)ureido) picolinic acid and the corresponding amide derivative
GB2068365B (en) * 1980-02-05 1983-12-14 Dow Chemical Co Fungicidal pyridyl arylureas
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0840623B1 (en) 1995-07-21 2007-07-18 Brown University Research Foundation Compositions for gene therapy comprising nucleic acid loaded polymeric microparticles
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
IL145941A (en) 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
EP1537075B1 (en) 2002-09-05 2009-07-01 Neurosearch A/S Diarylurea derivatives and their use as chloride channel blockers
WO2012103523A2 (en) 2011-01-27 2012-08-02 Samuel Rahbar Novel modulators of development of adipocyte and cancer cells
CN103709097A (zh) 2012-09-28 2014-04-09 中国科学院上海药物研究所 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用
CR20170094A (es) 2014-09-10 2017-05-08 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
CN109705031A (zh) 2018-11-29 2019-05-03 浙江泰达作物科技有限公司 一种吡啶苯基脲类化合物及其在化妆品中的应用
WO2020126968A2 (en) * 2018-12-20 2020-06-25 Bayer Aktiengesellschaft Urea derivatives

Similar Documents

Publication Publication Date Title
JP2024099041A5 (enExample)
JP2023533938A5 (enExample)
JP2021526133A5 (enExample)
JP2014500870A5 (enExample)
JP2021532162A5 (enExample)
JP2020533277A5 (enExample)
JP2007511504A5 (enExample)
JP2016506916A5 (enExample)
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2015512413A5 (enExample)
JP2016053042A5 (enExample)
JP2010540556A5 (enExample)
JP2013525458A5 (enExample)
JP2022071077A5 (enExample)
JP2009519243A5 (enExample)
JP2017511321A5 (enExample)
RU2014101626A (ru) Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
JP2024532845A5 (enExample)
JP2021514395A5 (enExample)
JP2012509265A5 (enExample)
JP2022541747A5 (enExample)
JP2014502599A5 (enExample)
JP2007505044A5 (enExample)
JP2009503110A5 (enExample)
JP2021532158A5 (enExample)